Mixed setup heading into August 4 — Amgen is trading below the Wall Street consensus price target, approaching a critical technical resistance just under $400, with options flow neutral and analyst estimates calling for a year-over-year EPS decline this quarter.
The Setup: A Recovery Rally Approaching a Ceiling
Amgen closed at $387.64 on July 29, down 1.39% on the session, but that single-day dip belies a meaningful recovery over the past two weeks. AMGN hit a 20-day low of $353.95 on July 15 and has since bounced +9.5%, posting a recent intraday high of $398.00 on July 28 before pulling back.
The 20-day trend is firmly UP, gaining 7.3% over that window, with trendline support at $359.21 and resistance at $398.00. The 100-day trend tells a more cautious story: the longer-term trend is classified as sideways with weak strength, though the stock is currently trading above its 100-day mean — a mildly bullish positioning signal. The scanner pattern reads "Near Breakout" with a WATCH signal, reflecting the fact that AMGN sits just 2.3% below its key resistance zone heading into a binary event.
The 20-day SMA stands at $368.88 and the 50-day SMA at $353.38, both well below the current price — meaning the stock is trading in an extended position relative to its recent averages going into the print. RSI is at 67.1, approaching overbought territory without quite reaching it. That is a constructive but not comforting setup: there is room to run on a beat, but limited cushion if Amgen disappoints.
A fresh positive catalyst arrived July 30: the European Medicines Agency's CHMP issued a positive opinion for an expanded Repatha indication in Europe for cardiovascular risk reduction — a meaningful regulatory win that reinforces the growth story for one of Amgen's key commercial franchises heading into the print.
What the Options Market Says
Options flow into this earnings event is best described as neutral-to-cautiously bullish. The overall options flow score sits at 65/100, with a mixed flow signal and a bullish MACD undercurrent. The options signal classification is NEUTRAL_BULLISH, though confidence is flagged as LOW, and the put/call ratio is running at parity (1.0) — neither side is pressing a strong directional bet.
On the open interest build ahead of earnings, call positioning is concentrated at the $440 strike (an OI increase of 3,190 contracts), with secondary call builds at $385. Put builds are clustering at $367.50 (1,253 contracts added) and $345 (1,030 contracts). The asymmetry here is notable: the largest single open interest position is the $440 call wall, sitting $52 above the current price — suggesting some traders are reaching for an outsized upside scenario, while downside hedging activity is centered much closer to spot.
The dealer gamma structure shows the call wall at $440 (42,650 contracts of open interest) and the put wall at $330 (19,142 contracts). This positions the stock in a broad corridor, with the call wall as the likely magnetic ceiling and the put wall as meaningful downside support in a stress scenario. The gamma bias is classified as bullish, meaning dealers' hedging activity currently tilts toward supporting price on dips rather than pressuring it.
The $440 call wall is $52 (13.4%) above the current price — a level that would require either a dramatic earnings beat or a significant upward re-rating. Options are not pricing that as the base case. Meanwhile, the stock's RSI at 67.1 and its position just 2.3% below 20-day resistance mean it is already carrying a portion of pre-earnings enthusiasm. Any guidance shortfall or pipeline setback could unwind that positioning quickly, with limited technical support until $357–$359.
Fundamentals & Estimates: A Quarter With a Tricky Comparison
The Q2 2026 consensus is asking for EPS of $5.62 (range: $4.99–$6.28) on revenue of approximately $9.42 billion (range: $9.10B–$9.63B). The revenue estimate represents roughly +2.7% year-over-year growth, while the EPS estimate is a -6.7% decline versus the $6.02 earned in Q2 2025 — a tough comparison driven in part by the ongoing weight of Horizon Therapeutics acquisition costs and amortization charges. That EPS dynamic is the single most important number to watch: even a modest beat could be received positively simply because the bar has been set below prior-year results.
For the full year 2026, the Street is modeling EPS of $22.35 (up ~2.3% YoY) on revenue of $37.73 billion (+2.7% YoY). Growth is modest but steady, with FY2027 consensus calling for a step-up to $23.44 EPS (+4.9%) and $38.66B in revenue.
Revision momentum is modestly positive: over the past 30 days, 2 analysts raised their EPS estimates versus 1 downward revision — a net positive signal heading into the print. Valuation sits at a forward P/E of 16.9x, which is reasonable for a large-cap biotech generating a 21% net profit margin and a striking 101.3% return on equity. The PEG ratio of 2.06x reflects the market paying a slight premium for that quality, given the low-single-digit growth profile.
Wall Street's consensus price target is $357.03 — with the stock trading at $387.64, AMGN is actually sitting 8.6% above the average analyst target. The breakdown is 4 strong buys, 10 buys, 17 holds, 2 sells, and 1 strong sell among the 34 analysts covering the name. That overweight of holds and the below-market consensus target suggest institutional expectations are already skeptical of near-term upside at current prices.
Key Levels to Watch
| Level | Price | Significance |
|---|---|---|
| Call Wall / Major Resistance | $440.00 | Largest OI concentration (42,650 contracts); ceiling in a blow-out scenario |
| 20-Day Resistance / Pattern Target | $398.00 | Recent high and trendline resistance; a breakout here would be technically significant |
| Current Price | $387.64 | Benchmark heading into the print |
| Near-Term Options Support | $367.50 | Put build zone; bears protecting this level pre-earnings |
| 20-Day Trendline Support | $359.21 | Key support; a close below here on earnings would turn the near-term trend negative |
| Scanner Pattern Support | $357.74 | Breakout pattern base; holding this level is essential to the bullish setup |
| Put Wall / Deep Support | $330.00 | Major dealer positioning floor; a move here would represent a ~15% sell-off |
If Amgen misses on revenue or cuts full-year guidance, the path lower runs through $367.50 (put build zone), then $359–$357 (trendline and pattern support), and potentially toward $330 where the put wall provides structural support. With the stock currently trading above the Wall Street mean price target, a disappointing print would face limited fundamental support at current levels.
Bottom Line
Amgen heads into Q2 2026 earnings on August 4 with momentum on its side — the stock has recovered +9.5% off its July lows and sits in a near-breakout pattern just below key $398 resistance. However, the setup carries real two-sided risk: the stock is already above the Street's mean target of $357, EPS is expected to fall year-over-year, and options flow confidence is low. A clean beat-and-raise — particularly any upward revision to full-year guidance — could drive a breakout toward $398 and potentially the $440 call wall over time. If it holds $359 on any post-earnings dip, the 20-day uptrend remains intact and dip buyers should be interested. But investors sitting in positions above $385 should be aware that the bar may already be partially priced in.
This article was generated by Tradestie Alpha Assistant using live market data (investment scores, options positioning, trendlines, and fundamentals) and reviewed before publication. It is for informational purposes only and is not financial advice. Do your own research before making investment decisions.